AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study -- Update
AbbVie picked up tavapadon as part of its $8.7 billion acquisition of Cerevel Therapeutics earlier this year. Prior to the deal closing, Cerevel had reported a successful Phase 3 study of tavapadon as ...
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease.
The Pharma Letter4d
AbbVie Phase III success with tavapadon in Parkinson’s
US pharma major AbbVie announced positive top-line results from its pivotal Phase III TEMPO-2 trial evaluating ...
Outsourcing-pharma4d
AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3 results
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's ...
Hope for Parkinson’s disease symptoms is found in late-stage drug study
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...
clinicaladvisor.com4d
Tavapadon Beneficial for Early Parkinson Disease in Flexible-Dose Trial
Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a selective ...
MarketWatch5d
AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study
AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon met the primary ...
AbbVie Says Phase 3 TEMPO-2 Study Of Tavapadon In Early Parkinson's Disease Met Main Goal
Monday said Phase 3 TEMPO-2 study evaluating tavapadon in early Parkinson's disease met its primary goal. In the ...
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom ...